Jan Thirkettle

Jan has more than 20 years’ experience of building cross functional teams to drive delivery of innovative technologies. He has built platforms and played a leadership role in the commercialisation of therapeutics across small molecule, biopharmaceutical and gene therapy modalities. Jan joined Transine Therapeutics from Freeline Therapeutics where he was start-up CEO then Chief Development Officer overseeing deployment of a novel AAV platform and a rapidly growing clinical-phase portfolio. Prior to this Jan spent close to 20 years at GSK in multiple senior roles spanning from Discovery to Manufacturing environments, latterly oversing the establishment of the Cell & Gene Therapy platform unit where he played a pivotal role in the commercialisation of Strimvelis, the first ex-vivo gene therapy to receive an EU Marketing Authorisation Application. He has served on multiple advisory boards in the CMC and regulatory space, playing a significant role in the shaping of the Cell and Gene therapy field. Jan holds an MA in Chemistry and a DPhil. in Biological Chemistry from Oxford University.